Application and prospect of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastasis from colorectal cancer.
10.3760/cma.j.cn112152-20200628-00603
- Author:
Si Cheng ZHOU
1
;
Wei PEI
1
;
Hai Tao ZHOU
1
;
Jian Wei LIANG
1
;
Zhi Xiang ZHOU
1
Author Information
1. Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Cytoreductive surgery;
Hyperthermic intraperitoneal chemotherapy;
Peritoneal metastasis;
Treatment application
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Colorectal Neoplasms/drug therapy*;
Combined Modality Therapy;
Cytoreduction Surgical Procedures;
Humans;
Hyperthermia, Induced;
Hyperthermic Intraperitoneal Chemotherapy;
Peritoneal Neoplasms/drug therapy*;
Peritoneum;
Prognosis;
Quality of Life;
Survival Rate
- From:
Chinese Journal of Oncology
2022;44(1):73-78
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer is one of the common malignant tumors in China, and its incidence is increasing with years. As the second most common metastatic site of colorectal cancer, peritoneum is difficult to diagnose early and with a poor prognosis. Systemic intravenous chemotherapy was used as the main treatment strategy for peritoneal metastasis in the past, but its systemic toxic and side effects were obvious, and it could not effectively control tumor progression. In recent years, the continuous development of surgical techniques, concepts, and equipment, as well as the introduction of new chemotherapy drugs and targeted drugs have significantly improved the quality of life and prognosis of patients with peritoneal metastasis of colorectal cancer. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can effectively eradicated the intraperitoneal free cancer cells and subclinical lesions, while reducing systemic side effects of chemotherapy drugs, and achieve the radical cure of the tumor at the macro and micro levels to the greatest extent. It has been used as the first-line treatment program for peritoneal metastasis of colorectal cancer at home and abroad. This article focuses on the analysis and summary of the survival efficacy, prognostic factor analysis, and chemotherapy safety of CRS+ HIPEC in the treatment of colorectal cancer peritoneal metastasis. The existing problems and controversies of HIPEC therapy are discussed simultaneously.
